SEO URLwww.firestrike.ai/deals/repertoire-immune-medicines-lilly-acquisition-2026
acquisitionAnnounced · Jan 29, 2026PharmaceuticalsSource · CredibleArticle · Factual
Lilly acquires Repertoire Immune Medicines
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$1.93B
Target
Repertoire Immune Medicines
Cambridge, Massachusetts
Acquirer
Lilly
Full Acquisition
Status
Announced
Lilly agreed to acquire Repertoire Immune Medicines. Reported deal value: $1.93B. Status: Announced. Sector: Pharmaceuticals. Target headquarters context: Cambridge, Massachusetts, United States.
This page summarizes publicly available information about the transaction as of 2026-01-29. Figures and status may change as filings and press coverage update.
Lilly signs up to $1. 93 billion deal with Repertoire for autoimmune therapiesJan 29 - Drugmaker Eli Lilly is partnering with Repertoire Immune Medicines in a deal worth up to $1. 93 billion to develop therapies for multiple autoimmune diseases,
Deal timeline
Announced
Jan 29, 2026 · in.marketscreener.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Pharmaceuticals with a reported deal value of $1.93B. Figures and status may change as sources update.
Sources: in.marketscreener.com · Primary article · FireStrike proprietary index